Elevance Health, Inc. (ELV) operates as a health benefits company with a market cap of $74.7 billion, supporting consumers and communities across the healthcare journey. Despite a recent drop of 26.2% from its 52-week high, ELV stock has gained 9.2% in the past three months, outperforming the Nasdaq Composite.

However, Elevance has underperformed the Nasdaq market in the long term, with stock prices declining 8.2% YTD and 15.8% over the past 52 weeks. It has consistently remained below its 200-day moving average, indicating a bearish trend.

Following Q3 results, Elevance’s stock prices dropped 1.2% despite reporting better-than-expected results. The company saw a 12% year-over-year surge in overall topline to $50 billion, with adjusted EPS at $6.03, beating consensus estimates by 21.1%. Despite underperforming peers like The Cigna Group, Elevance has shown solid growth in premium collection and product revenues.

Read more at Yahoo Finance: Is Elevance Health Stock Outperforming the Nasdaq?